Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond

M Platten, EAA Nollen, UF Röhrig, F Fallarino… - Nature reviews Drug …, 2019 - nature.com
Abstract l-Tryptophan (Trp) metabolism through the kynurenine pathway (KP) is involved in
the regulation of immunity, neuronal function and intestinal homeostasis. Imbalances in Trp …

Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?

S Demaria, C Guha, J Schoenfeld… - Journal for …, 2021 - pmc.ncbi.nlm.nih.gov
Recent evidence indicates that ionizing radiation can enhance immune responses to
tumors. Advances in radiation delivery techniques allow hypofractionated delivery of …

Discovery of IDO1 inhibitors: from bench to bedside

GC Prendergast, WP Malachowski… - Cancer …, 2017 - aacrjournals.org
Small-molecule inhibitors of indoleamine 2, 3-dioxygenase-1 (IDO1) are emerging at the
vanguard of experimental agents in oncology. Here, pioneers of this new drug class provide …

The therapeutic potential of targeting tryptophan catabolism in cancer

CA Opitz, LF Somarribas Patterson… - British journal of …, 2020 - nature.com
Based on its effects on both tumour cell intrinsic malignant properties as well as anti-tumour
immune responses, tryptophan catabolism has emerged as an important metabolic regulator …

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

AJ Muller, MG Manfredi, Y Zakharia… - Seminars in …, 2019 - Springer
With immunotherapy enjoying a rapid resurgence based on the achievement of durable
remissions in some patients with agents that derepress immune function, commonly referred …

Indoleamine 2, 3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy

Y Guo, Y Liu, W Wu, D Ling, Q Zhang, P Zhao, X Hu - Biomaterials, 2021 - Elsevier
Abstract Indoleamine 2, 3-dioxygenase (IDO) as a principle enzyme in tryptophan (Trp)
catabolism, modulates immune responses and promotes cancer progression. In recent …

IDO expression in cancer: different compartment, different functionality?

A Meireson, M Devos, L Brochez - Frontiers in immunology, 2020 - frontiersin.org
Indoleamine 2, 3-dioxygenase 1 (IDO1) is a cytosolic haem-containing enzyme involved in
the degradation of tryptophan to kynurenine. Although initially thought to be solely …

Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment

S Zhu, Y Wang, J Tang, M Cao - Frontiers in immunology, 2022 - frontiersin.org
Emerging evidence indicates that the induction of radiotherapy (RT) on the immunogenic
cell death (ICD) is not only dependent on its direct cytotoxic effect, changes in the tumor …

Radiation-induced bystander and abscopal effects: important lessons from preclinical models

E Daguenet, S Louati, AS Wozny, N Vial, M Gras… - British journal of …, 2020 - nature.com
Radiotherapy is a pivotal component in the curative treatment of patients with localised
cancer and isolated metastasis, as well as being used as a palliative strategy for patients …

Current state of melanoma therapy and next steps: battling therapeutic resistance

A Fateeva, K Eddy, S Chen - Cancers, 2024 - mdpi.com
Simple Summary Skin cancer is the most common cancer type worldwide, and melanoma is
its most aggressive and deadly form. In the past few decades, targeted therapy and …